The Impact of Ablative Doses on Survival for Patients Treated with Definitive Radiotherapy for Intrahepatic Cholangiocarcinoma

Abstract

receiving surgery upfront, nearly half (45.1%) received adjuvant radiation therapy, which is associated with higher toxicity and poorer local control as compared to neoadjuvant treatment, and 40.1% received no adjuvant therapy at all, which could lead to worse cancer outcomes. Further research is needed to better elucidate patient and systems-level factors contributing to these disparities in care.